FIELD: biotechnology, virology. SUBSTANCE: method involves preparing the purified particle of human hepatitis B surface antigen consisting of, wt. -%: S24 kDa nonglycosylated, 6.24%; S27 kDa glycosylated, 15.6%; pre-S2-33 kDa monoglycosylated, 10.8%; pre-S1-39 kDa nonglycosylated, 6.1%; pre-S1-41 glycosylated, 1.9%, and pre-S2-36 kDa diglycosylated, 3.2%. On the basis of the indicated particle vaccine against hepatitis B has been prepared. EFFECT: higher efficiency. 8 cl, 4 tbl, 7 dwg
Authors
Dates
1997-06-10—Published
1990-02-07—Filed